Morphic forms of trilaciclib and methods of manufacture thereof

US12168666B2 · kind B2 · utility

Assignee

• G1 Therapeutics, Inc. · US

Inventors

• Stephen E. Schneider · Morrisville, US
• Alexander Smith · Apex, US
• Hannah S. White · Chapel Hill, US
• Jay Copeland Strum · Hillsborough, US
• Jaroslaw Mazurek · Amsterdam, NL

Key dates

• Filing date: Apr 21, 2021
• Grant date: Dec 17, 2024
• Expiry date: Feb 26, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An advantageous isolated morphic form of trilaciclib which is 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.